Skip to main content

Advertisement

Table 1 IC50 values of drugs in glioma tumor-initiating cells and U87 cultured in agarose

From: Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells

Drugs GSC11 GSC47 GSC20 GSC2 U87
Receptor tyrosine kinase inhibitors
 Erlotinib (μM) 0.11 ± 0.03 0.49 ± 0.15 0.82 ± 0.34 3.08 ± 0.55 3.72 ± 0.60
 Lapatinib (μM) 0.64 ± 0.22 1.86 ± 0.16 4.39 ± 1.08 3.04 ± 0.99 7.01 ± 2.20
 Sorafenib (μM) 2.59 ± 0.50 1.09 ± 0.44 2.21 ± 0.16 3.51 ± 0.25 5.24 ± 0.01
 Imatinib (μM) 6.37 ± 0.90 NE 11.0 ± 1.57 6.28 ± 2.24 3.24 ± 2.10
Non-receptor kinase inhibitors
 U0126 (μM) 14.0 ± 4.72 18.0 ± 3.25 4.69 ± 1.33 11.0 ± 0.25 11.1 ± 5.35
 BKM120 (μM) 0.41 ± 0.05 0.46 ± 0.21 0.36 ± 0.05 0.49 ± 0.10 0.59 ± 0.21
 PP2 (μM) 1.93 ± 0.50 NE 6.39 ± 2.46 4.33 ± 0.34 NA > 20
Transcription factor inhibitors
 WP1066 (μM) 2.46 ± 0.62 NE 1.55 ± 0.13 1.96 ± 0.13 1.59 ± 0.40
 Myc II (μM) 22.3 ± 3.57 NE 13.3 ± 1.50 19.0 ± 3.47 27.0 ± 5.68
DNA cross-linking agent
 BBR3610 (nM) 46.6 ± 23.0 NE 87.3 ± 33.5 117.3 ± 71 1.46 ± 1.26
  1. Data are means ± 95 % confidence intervals of at least two independent experiments
  2. NE Not examined, NA Not available, Myc II c-Myc inhibitor II